DR. REDDY'S LABORATORIES, INC. et al. vs. Novo Nordisk A/S

Explore the PTAB proceeding IPR2024-00009 filed by DR. REDDY'S LABORATORIES, INC. et al. on 2023-10-20. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2024-00009

Filing Date

2023-10-20

Accorded Filing Date

2023-10-20

Institution Decision Date

2024-04-25

Last Modified Date

2025-01-10

Proceeding Type

IPR

Termination Date

2025-01-10

Trial Status

Terminated-Settled

Parties & Counsel

Petitioner

DR. REDDY'S LABORATORIES, INC. et al.

Represented By

Wong, Jovialet al

Patent Owner / Respondent

Novo Nordisk A/S

Represented By

Baughman, Jonet al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Patent Information

1 Patent Involved

Respondent Application Number 15656042

Respondent Patent Number 10335462

External Links

Espacenet

Google Patents

Respondent Inventor Christine Bjoern Jensen

Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Address and Attorney/Agent Information

5 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name NOVO NORDISK INC. - INTELLECTUAL PROPERTY DEPARTMENT

Customer Number 23650

Address 800 Scudders Mill Road, Plainsboro, NJ, 08536, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
56129	Wesley Nicolas	609-786-5418
62124	Leon Lum	609-786-4172
63996	Elizabeth Dingess-Hammond	317-433-3689
64519	Jianjie Hu	609-786-4129
74995	Kathryn Jones	804-426-7196

Proceeding Documents

145

Termination Decision: Post-DI Settlement TERMINATE

2025-01-10 FILING PARTY: BOARD

Download

Order: On Protective Orders and Motions to Seal ORDER

2025-01-10 FILING PARTY: BOARD

Download

Order: Order on Motions to Expunge ORDER

2025-01-10 FILING PARTY: BOARD

Download

Decision Granting Institution of Inter Partes Review Granting Motion for Joinder OTHER

2024-04-25 FILING PARTY: BOARD

Download

2026

EX2026 - Excerpt of Opening Expert Report of Dr. Paul Dalby Regarding Invalidity of U.S. Patent No. 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del.) Exhibit

2024-04-03 FILING PARTY: PATENT OWNER

Download

DR. REDDY'S LABORATORIES, INC. et al. vs. Novo Nordisk A/S

Proceeding Overview

Parties & Counsel

Petitioner

DR. REDDY'S LABORATORIES, INC. et al.

Represented By

Patent Owner / Respondent

Novo Nordisk A/S

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

Termination Decision: Post-DI Settlement TERMINATE

Order: On Protective Orders and Motions to Seal ORDER

Order: Order on Motions to Expunge ORDER

Decision Granting Institution of Inter Partes Review Granting Motion for Joinder OTHER

EX2026 - Excerpt of Opening Expert Report of Dr. Paul Dalby Regarding Invalidity of U.S. Patent No. 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del.) Exhibit

EX2024 - Excerpt of Opening Expert Report of Dr. John Bantle Regarding Invalidity of U.S. Patent No. 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del.) Exhibit

Patent Owner's Further Authorized Reply OTHER

EX2025 - Excerpt of Opening Expert Report of William J. Jusko, Ph.D. Regarding Invalidity of U.S. Patent No. 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del.) Exhibit

Updated Exhibit List NOTICE

District Court Order re Trial Date Exhibit

ORDER Conduct of the Proceeding 37 C.F.R. § 42.5 ORDER

Proposed Stipulation Exhibit

Patent Owner's Sur-Reply OTHER

Petitioners’ Reply To Patent Owner’s Preliminary Response REPLYTOOPP

Exhibit 3001 Exhibit

EX2021 - Compilation of Rule 30(b)(1) Deposition Notices, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del.) Exhibit

EX2010 - Excerpt of Novo Nordisk’s Second Amended Disclosures to Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories, Inc., In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. July 28, 2023) Exhibit

EX2023 - Notice of Service for Defendants’ Supplemental Invalidity Contentions, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Nov. 6, 2023). Exhibit

EX2018 - Excerpt of Defendants’ Supplemental Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Nov. 2, 2023) Exhibit

EX2013 - Waiver of Service of Summons for Dr. Reddy’s Laboratories Ltd., Novo Nordisk Inc. v. Dr. Reddy’s Lab’ys Ltd., No. 1:22-cv-00298-CFC, Dkt. 7 (D. Del. Mar. 4, 2022) Exhibit

EX2011 - U.S. Patent No. 8,114,833 Exhibit

EX2006 - Scheduling Order, Novo Nordisk Inc. v. Rio Biopharms., Inc., No. 1:22-cv-00294-CFC, Dkt. 22 (D. Del.) Exhibit

EX2008 - Claim Construction Order, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC, Dkt. 148 (D. Del. July 25, 2023) Exhibit

EX2016 - Transfer Order, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC, Dkt. 1 (D. Del. Aug. 5, 2022) Exhibit

EX2012 - Waiver of Service of Summons for Dr. Reddy’s Laboratories, Inc., Novo Nordisk Inc. v. Dr. Reddy’s Lab’ys Ltd., No. 1:22-cv-00298-CFC, Dkt. 6 (D. Del., Mar. 4, 2022) Exhibit

EX2019 - Novo Nordisk Production Letter, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Oct. 17, 2023) [REDACTED] Exhibit

EX2009 - Joint Stipulation and Order Amending Scheduling Order, In re: Ozempic (Semaglutide) Patent Litigation, MDL No. 22-MD-03038-CFC, Dkt. 268 (D. Del. Dec. 1, 2023) Exhibit

EX2002 - Petition for Inter Partes Review, Mylan Pharms. Inc. v. Novo Nordisk A/S, IPR2023-00724, Pap.1 (Mar. 16, 2023) Exhibit

EX2022 - Notice of Service for Defendants’ Initial Invalidity Contentions, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Oct. 20, 2022) Exhibit

EX2004 - Stipulation and Order Regarding Trial of the MPI Ozempic Litigation, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC, Dkt. 245 (D. Del. Oct. 31, 2023) Exhibit

EX2007 - Excerpt of Transcript of Dec. 13, 2023 Claim Construction Hearing, Novo Nordisk Inc. v. Mylan Pharmaceuticals Inc., No. 23-101-CFC (D. Del. Dec. 13, 2023) Exhibit

EX2014 - Excerpt of Redacted Patent Owner’s Response, Mylan Pharms. Inc. v. Novo Nordisk A/S, IPR2023-00724, Pap.30 (Jan. 17, 2023) Exhibit

EX2001 - Excerpt of Defendants’ Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Oct. 20, 2022) Exhibit

Preliminary Response POPR

EX2005 - Nov. 29, 2023 Email from E. Goldschlager to Counsel, re: IPR2023-00724 – Request for Conference Call Exhibit

EX2020 - Novo Nordisk Production Letter, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Oct. 17, 2023) [REDACTED] Exhibit

EX2003 - Declaration of Sayem Osman Exhibit

Joint Stipulation Regarding Petitioners' Motion for Joinder OTHER

Order: Conduct of the Proceeding 37 C.F.R. sec. 42.5 ORDER

Power of Attorney and Designation of Lead and Back-Up Counsel NOTICE

Patent Owner's Mandatory Notices NOTICE

Patent Owner's Mandatory Notices NOTICE

Patent Owner's Mandatory Notices NOTICE

Power of Attorney and Designation of Lead and Back-Up Counsel NOTICE

Power of Attorney and Designation of Lead and Back-Up Counsel NOTICE

Notice: Notice filing date accorded NOTICE

Drucker, Enhancing Incretin Action 26 DIABETES CARE 2929 (2003) Exhibit

U.S. Patent No. 7,022,674 Exhibit

U.S. Patent App. Pub. 2004/0102486 Exhibit

Clinical Trial No. NCT00851773 Exhibit

WO 03/002136 Exhibit

CV of William J. Jusko, Ph.D. Exhibit

“Last Update Posted” definition from ClinicalTrials.gov Exhibit

Landersdorfer, Pharmacokinetic (47(7) CLINICAL PHARMACOKINETICS 417 (2008) Exhibit

U.S. Patent No. 5,512,549 Exhibit

Scheduling Order, No. 22-294 (CFC), D. Del. June 30, 2022, ECF No. 22 Exhibit

Clinical Trial No. NCT00696657 Exhibit

Motion : DLR '462 PETITIONERS’ MOTION FOR JOINDER MOTION

ClinicalTrials.gov Background, CLINICALTRIALS.GOV Exhibit

Transfer Order, In re: Ozempic, No. 3038 (MDL Aug. 5, 2022) Exhibit

Lovshin, Incretin-Based Therapies for Type 2 Diabetes Mellitus, 5 NATURE RE Exhibit

Declaration of Dr. Maureen M. Donovan Exhibit

Rohatagi, Model-Based Development, 48 J. CLINICAL PHARMACOLOGY 1420 (2008) Exhibit

Knudsen, GLP-1 Derivatives, 26 DRUGS OF THE FUTURE 677 (2001) Exhibit

WO 2006/097537 Exhibit